Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 298Neoplasms 179Breast Neoplasms 170Colorectal Neoplasms 107Neoplasm Metastasis 100Melanoma 99Multiple Myeloma 93Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 80Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 67Lymphoma, Non-Hodgkin 61Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 47Small Cell Lung Carcinoma 46Urinary Bladder Neoplasms 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 34Glioblastoma 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Immunologic Deficiency Syndromes × Clear all
NCT04554914 2026-04-27

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Pierre Fabre Medicament

Phase 2 Active not recruiting
190 enrolled
LymphoidSarcoma

Immunologic Deficiency Syndromes, Leiomyosarcoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡